Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 5/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.43 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ITK | Q08881 | 1/20 | 0.43 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | ULK1 | O75385 | 1/20 | 0.42 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16070363 | 0.90 | POLB (0.44) | PTK2FGFR1FGFR4EGFRITK | |
| SCHEMBL16070358 | 0.89 | FGFR3 (0.47) | PTK2SYKFGFR1FGFR4EGFR | |
| SCHEMBL16070502 | 0.89 | CDK9 (0.46) | PTK2AURKAFGFR1FGFR4ALKBH1 | |
| SCHEMBL16070347 | 0.89 | SCN9A (0.41) | PTK2SYKFGFR1FGFR4EGFR | |
| SCHEMBL16069792 | 0.88 | PTK2 (0.44) | PTK2AURKAFGFR1FGFR4CYP3A4 | |
| SCHEMBL17469985 | 0.86 | PTK2 (0.45) | PTK2FGFR1FGFR4CYP3A4CYP2D6 | |
| SCHEMBL16070250 | 0.86 | PTK2 (0.45) | PTK2FGFR1FGFR4CYP3A4CYP2D6 | |
| SCHEMBL16070230 | 0.86 | ULK1 (0.48) | PTK2SYKFGFR1FGFR4ULK1 | |
| SCHEMBL16070248 | 0.85 | FGFR1 (0.38) | PTK2SYKFGFR1FGFR4EGFR | |
| SCHEMBL16070342 | 0.84 | FGFR3 (0.41) | PTK2FGFR1FGFR4ALKBH1HPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9701680-B2 | Pyrimidine and pyridine compounds and their usage | HUTCHISON MEDIPHARMA LIMITED (CN) | 2017-07-11 | — | — | US | disclosed |
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-01-28 | — | — | US | disclosed |
| WO-2014139465-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024021-A1 | NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND THEIR USAGE | FGFR3, FGFR1, FGFR4 | PTK2 1034/4885AURKA 172/4885SYK 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.